26
Oct

Clearing Up Some Confusion Around Establishment Registrations

FDA requires registration of facilities for everything from animal/veterinary and human drugs, medical devices, cosmetics, food, tobacco, radiation-emitting products, and vaccines, blood, and biologics. This blog focuses on the Drug Establishment Registration (DER) requirements. On September 25, 2026, a whirlwind of emails came through to those of us in the pharmaceutical world proclaiming that the […]

Read More
20
Oct

Web Page Launched for Stakeholder Engagement to Bring New OTC Products to Market

On October 20, 2026 the FDA announced a webpage (here) describe FDA’s plan and ongoing activities to engage stakeholders on identifying approved prescription drugs that may be promising candidates for nonprescription marketing and provides answers to frequently asked questions about the nonprescription drug development process. The FDA website discusses the past history in the development […]

Read More
10
Sep

FDA Issues Final Order Removing Two Sunscreen Ingredients from Monograph

FDA announced today (here) that, after reviewing timely submitted comments to its September 27, 2021 notice of availability of the proposed order OTC000008 titled Amending Over-the-Counter (OTC) Monograph M020, that it is removing two ingredients, para-aminobenzoic Acid (PABA) and trolamine salicylate from the monograph. The notice states that “FDA has determined that there are no […]

Read More
14
Aug

FDA Updates Container Closure System Packaging Guidance

The Agency has issued a 37-page draft guidance (here), that describes FDA’s current thinking regarding a wide range of issues regarding various container closure systems, packaging components and testing requirements to ensure that the proposed container closure system is appropriate for the proposed drug product. FDA says that when finalized, this draft guidance will “supersede […]

Read More
29
Jul
FDA Announces Over-the-Counter Drug Monograph User Fees for FY 2027

FDA Announces Over-the-Counter Drug Monograph User Fees for FY 2027

In a pre-publication Federal Register Notice (FRN) (here) on FDA’s webpage on Over-The-Counter Monograph Drug User Fee Program (OMUFA) (here), the FDA announced the OTC Monograph User Fees for FY 2027. The Notice explains how the fees were set and the change where “beginning with FY 2027, FDA is consolidating the separate facility fee notices […]

Read More
24
Jul

FDA Approves First Acetaminophen/Naproxen Combination Product for Pain

Today, the FDA approved a combination of acetaminophen and naproxen sodium tablets, 325 mg/110 mg for minor pain as an over-the-counter product for 12-hour pain relief. FDA says in a press release (here): “This nonprescription product is indicated for the temporary relief of minor aches and pains due to headache, backache, muscular aches, toothache, menstrual […]

Read More
09
Jun

Sunscreen Ingredient Receives GRASE Status

In today’s prepublication of the Federal Register, the FDA, in response to an over-the-counter (OTC) monograph order request (OMOR), announced the availability of an amended final administrative order (OTC000039) for sunscreen ingredients permitting the over-the counter (OTC) use of the ingredient bemotrizinol, considering it to be generally recognized as safe and effective (GRASE) for its […]

Read More
23
Dec
FDA Announces OMOR Fee Rates for FY 2026 - Lachman Blog

FDA Announces OMOR Fee Rates for FY 2026

In a prepublication Federal Register notice here, the FDA announced its FY 2026 OTC monograph order requests (OMOR). The Agency has indicated that it will publish the FY 2026 OMUFA facility fee rates (i.e., monograph drug facility (MDF) and contract manufacturing organization (CMO) facility fee rates) in a subsequent Federal Register notice. There are two tiers of […]

Read More
1 2 … 9